CTSU established the use of very large streamlined randomised trials to assess the effects of widely practicable treatments on mortality and major morbidity in common diseases. Such trials typically randomise some tens of thousands of patients and, as a result, have provided clear and reliable information about the effects of several treatments. In cardiovascular disease, CTSU designed and ran the four International Studies of Infarct Survival (ISIS-1 to ISIS-4: randomising 140,000 patients), whose results have substantially improved the emergency treatment of heart attacks—and, consequently, are saving tens of thousands of lives each year. CTSU is currently conducting several mega-trials of the effects of different treatments for vascular diseases and for cancers (as well as for certain other conditions). In addition the unit runs MRC leukaemia trials, and helps others with trial design and analysis.

Professor Colin Baigent presented 'What makes a randomised trail reliable? (video and presentation)' at the HRB Clinical Research Facility Cork.

3C (A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial)

ASCEND (A Study of Cardiovascular Events iN Diabetes)

ATLAS (Adjuvant Tamoxifen Longer Against Shorter)

BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D)

HPS (MRC/BHF Heart Protection Study)

HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events)

HPS3/TIMI55 – REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification)

Leukaemia trials: Adult ALL, UKALL 2003

SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine)

SHARP (Study of Heart and Renal Protection)

CTSU also provides randomisation services for studies such as ACST2 (Asymptomatic Carotid Surgery Trial 2).